Benralizumab Outperforms Steroids in Treating Asthma and COPD Flare-Ups
Benralizumab injection improved respiratory symptoms within 28 days and reduced treatment failures by fourfold after 90 days compared to standard steroid therapy.
Benralizumab injection improved respiratory symptoms within 28 days and reduced treatment failures by fourfold after 90 days compared to standard steroid therapy.
Benralizumab injection improved respiratory symptoms within 28 days and reduced treatment failures by fourfold after 90 days compared to standard steroid therapy.
Read MoreFindings from a multinational study demonstrated that 92% of patients using benralizumab could safely reduce inhaled steroid dose, and more than 60% could stop all use.Â
Read MoreSevere asthma patients account for as much as 60% of all asthma healthcare costs, and proper management of severe disease is essential.
Read MoreLevels of inflammatory cytokines in patients with severe asthma may predict responses to the monoclonal antibody benralizumab, a study in the Journal of Asthma suggests.
Read MoreA five-year trial found at least 75% of Fasenra-treated asthma patients with elevated blood eosinophil levels had zero exacerbations each year of the open-label period.
Read MoreBenralizumab (Fasenra) has been approved for self-administration by patients and caregivers by the US FDA, according to AstraZeneca.
Read MorePatients with severe eosinophilic asthma treated long-term with benralizumab (Fasenra) continued to experience fewer exacerbations and improved pulmonary function and quality of life.
Read MoreCertain key clinical characteristics in patients with severe asthma may help clinicians ID those who may benefit from additional targeted drug therapy, such as benralizumab.
Read More